Trial · NCT01340014

Patient Preference Comparison of AZARGA Versus COSOPT

NCT01340014, Phase 4, Completed, Alcon Research; results first posted 2013-12-13

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Patient Preference Comparison of AZARGA Versus COSOPT. Trials, record NCT01340014. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01340014

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Patient Preference Comparison of AZARGA Versus COSOPT
NCT number: NCT01340014
Status: Completed
Phases: Phase 4
Enrollment: 112 participants, actual
Lead sponsor: Alcon Research
Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Brinzolamide 1.0% + Timolol 0.5% ophthalmic suspension, Dorzolamide 2.0% + Timolol 0.5% ophthalmic solution
First posted: 2011-04-21
Last updated: 2014-02-10
Other registries' IDs: eudract:2010-024244-15
Results first posted: 2013-12-13

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Preferred Treatment	At the end of both periods, Day 15	The participant completed a questionnaire on the Day 15 visit (ie, after administration of both study medications) consisting of a single preference question: "Thinking about the comfort of the two medications (1st and 2nd) that you took during this study, which medication do you prefer?" Preferred treatment is presented as a percentage.
Secondary	Ocular Discomfort	Day 7 of each period	Ocular discomfort was assessed by the participant 1 minute after instillation of the study medication. Ocular discomfort was rated on a 10-point scale (0=no discomfort, 9=substantial discomfort).

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Preferred Treatment	At the end of both periods, Day 15	This reporting group includes all participants who completed both treatment periods and completed the preference questionnaire, as treated.	Percentage of participants	NUMBER
SECONDARY	Ocular Discomfort	Day 7 of each period	This reporting group includes all participants who completed both treatment periods and completed the preference questionnaire, as treated, minus any missing responses.	Units on a scale	MEAN

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Preferred Treatment	AZARGA	60.2		Percentage of participants
Preferred Treatment	COSOPT	39.8		Percentage of participants
Ocular Discomfort	AZARGA	2.6	Standard Deviation 2.27	Units on a scale
Ocular Discomfort	COSOPT	3.7	Standard Deviation 2.63	Units on a scale

Source ClinicalTrials.gov

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Period 1, First 7 Days	STARTED	AZARGA/COSOPT	55
Period 1, First 7 Days	STARTED	COSOPT/AZARGA	57
Period 1, First 7 Days	COMPLETED	AZARGA/COSOPT	53
Period 1, First 7 Days	COMPLETED	COSOPT/AZARGA	57
Period 1, First 7 Days	NOT COMPLETED	AZARGA/COSOPT	2
Period 1, First 7 Days	NOT COMPLETED	COSOPT/AZARGA	0
Period 2, Second 7 Days	STARTED	AZARGA/COSOPT	53
Period 2, Second 7 Days	STARTED	COSOPT/AZARGA	57
Period 2, Second 7 Days	COMPLETED	AZARGA/COSOPT	53
Period 2, Second 7 Days	COMPLETED	COSOPT/AZARGA	56

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	AZARGA
Total, all-cause mortality	COSOPT
Total, other adverse events	AZARGA	0	112
Total, other adverse events	COSOPT	0	112
Total, serious adverse events	AZARGA	0	112
Total, serious adverse events	COSOPT	0	112

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
AZARGA vs COSOPT: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01340014

GET https://conductscience.org/api/trials/v1/NCT01340014/registered

API reference For AI assistants